Cure Multiple Myeloma Corporation
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2015 | 88,604 | 87,388 | 1,216 | 0.2 | 0% |
| 2016 | 95,496 | 93,485 | 2,011 | 0.4 | 0% |
| 2017 | 143,790 | 132,216 | 11,574 | 1.3 | 0% |
| 2018 | 161,539 | 154,063 | 7,476 | 1.7 | 0% |
| 2019 | 187,540 | 194,544 | −7,004 | 0.9 | 0% |
| 2020 | 106,647 | 24,292 | 82,355 | 48.2 | 0% |
| 2021 | 186,482 | 151,955 | 34,527 | 10.4 | 0% |
| 2022 | 181,255 | 204,746 | −23,491 | 6.4 | 0% |
| 2023 | 214,660 | 295,136 | −80,476 | 1.1 | 0% |
In its most recent public year (2023), this organization spent $80,476 more than it brought in. Its reserves stood at about 1.1 months of spending. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Cure Multiple Myeloma Corporation's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works